Highly successful drugs, sometimes known as blockbusters, have a great impact on healthcare as they treat a large number of patients, and are most frequently indicated in common, often chronic conditions. This guarantees a high level of usage and therefore a profitable drug, however the premium placed upon producing such drugs can result in smaller conditions being neglected. Due to the private nature of the pharmaceutical industry, and because there is more money in developing ‘blockbuster’ drugs capable of treating common diseases, the healthcare industry faces numerous challenges as rarer diseases which may be just as life-threatening see fewer drugs entering trials. In this article, we propose a new business model using the available technologies to achieve the necessary transformation.